These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 27030540

  • 1. Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.
    Klamroth R, Miesbach W, Staritz P, German EffeKt Study Group.
    Haemophilia; 2016 Sep; 22(5):684-91. PubMed ID: 27030540
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
    Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ, International Kogenate-FS Study Group.
    Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries.
    Gouider E, Rauchensteiner S, Andreeva T, Al Zoebie A, Mehadzic S, Nefyodova L, Brunn M, Tueckmantel C, Meddeb B.
    Haemophilia; 2015 May; 21(3):e167-e175. PubMed ID: 25649665
    [Abstract] [Full Text] [Related]

  • 6. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A.
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.
    Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R.
    Haemophilia; 2007 Jul; 13(4):351-6. PubMed ID: 17610547
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D.
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
    Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A, Coganate FS Study Group.
    Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
    [Abstract] [Full Text] [Related]

  • 12. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, Scharrer I.
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [Abstract] [Full Text] [Related]

  • 13. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E.
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [Abstract] [Full Text] [Related]

  • 14. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M, investigators of the LEOPOLD Kids Trial.
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, Park SK.
    J Korean Med Sci; 2018 Jan 01; 33(1):e5. PubMed ID: 29215814
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.